ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of |
(I.R.S. Employer | |
Incorporation or Organization) |
Identification No.) | |
(Address of principal executive offices) |
(Zip Code) |
Title of each class |
Name of exchange on which registered | |
The |
Large accelerated filer |
☐ |
☒ | ||||
Non-accelerated filer |
☐ |
Smaller reporting company |
||||
Emerging growth company |
Auditor Name: |
Auditor Location: |
Auditor Firm ID: | ||||||
1 |
||||
7 |
||||
15 |
||||
18 |
||||
21 |
||||
Name |
Age |
Position(s) | ||
Executive Officers |
||||
Nassim Usman, Ph.D. |
62 |
President and Chief Executive Officer | ||
Grant Blouse |
51 |
Chief Scientific Officer | ||
Seline Miller |
53 |
Principal Accounting Officer & Interim Chief Financial Officer | ||
Non-Executive Directors |
||||
Augustine Lawlor(1)(2) |
65 |
Chairman of the Board | ||
Andrea Hunt(3) |
62 |
Director | ||
Eddie Williams(3) |
66 |
Director | ||
Errol B. De Souza(2) |
68 |
Director | ||
Geoffrey Ling, M.D., Ph.D.(2) |
65 |
Director | ||
Jeanne Y. Jew(1) |
58 |
Director | ||
Sharon Tetlow(1) |
62 |
Director |
(1) | Member of the Audit Committee. |
(2) | Member of the Compensation Committee. |
(3) | Member of the Governance and Nominating Committee. |
• | the appointment, compensation, retention and oversight of any independent registered public accounting firm that Catalyst engages to issue an audit report, or to perform other audit, review or attest services, for its financial statements, and evaluating auditor independence; |
• | receiving and reviewing reports of management and the independent registered public accounting firm regarding the annual audit process, as well as the review process for its interim financial statements; |
• | reviewing with management significant accounting issues, policies relating to its financial statements and its cash management program; |
• | discussing with management and the independent registered public accounting firm its exposure to material risks and the adequacy of its risk management activities; |
• | reviewing management’s assessment of the effectiveness of, and its independent registered public accounting firm’s report on, its internal control over financial reporting; |
• | monitoring the rotation of partners of the independent registered public accounting firm on our engagement team as required by law; |
• | approving, to the extent required by applicable law or Nasdaq listing standards or by its related person transactions policy, related person transactions; |
• | establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls or auditing matters; |
• | responding to any report of evidence of a material violation of the securities laws or breach of fiduciary duty that it receives; and |
• | preparing the report of the audit committee required by applicable SEC rules to be included in its annual proxy statement. |
Board Size: |
| |||||||||||||||
Total Number of Directors |
7 | |||||||||||||||
Gender: | Male |
Female |
Non- Binary |
Gender Undisclosed |
||||||||||||
Number of directors based on gender identity |
2 | 2 | — | 3 | ||||||||||||
Number of directors who identify in any of the categories below: |
||||||||||||||||
African American or Black |
1 | — | — | — | ||||||||||||
Alaskan Native or American Indian |
— | — | — | — | ||||||||||||
Asian |
— | 2 | — | — | ||||||||||||
Hispanic or Latinx |
— | — | — | — | ||||||||||||
Native Hawaiian or Pacific Islander |
— | — | — | — | ||||||||||||
White |
— | — | — | — | ||||||||||||
Two or More Races or Ethnicities |
— | — | — | — | ||||||||||||
LGBTQ+ |
— | |||||||||||||||
Undisclosed |
4 |
• | Nassim Usman, Ph.D., our President and Chief Executive Officer; |
• | Grant Blouse, our Chief Scientific Officer; |
• | Seline Miller, our Interim Chief Financial Officer; |
• | Clinton Musil, our former Chief Financial Officer; and |
• | Howard Levy, our former Chief Medical Officer. |
Name and principal position |
Year |
Salary ($) |
Bonus ($) |
Option Awards ($) (1) |
Non-Equity Incentive Plan Compensation ($) (2) |
All Other Compensation ($) (3) |
Total ($) |
|||||||||||||||||||||
Nassim Usman, Ph.D. President and Chief Executive Officer |
2021 | 595,000 | — | 622,642 | — | 18,109 | 1,235,751 | |||||||||||||||||||||
2020 | 574,244 | — | 640,437 | 178,750 | 16,191 | 1,409,622 | ||||||||||||||||||||||
Grant Blouse Chief Scientific Officer |
2021 | 407,333 | 77,324 | 252,037 | — | — | 736,694 | |||||||||||||||||||||
Seline Miller Interim Chief Financial Officer |
2021 | 201,426 | 53,455 | 58,458 | — | — | 313,339 | |||||||||||||||||||||
Clinton Musil (4) Former Chief Financial Officer |
2021 | 389,734 | — | 239,890 | — | 20,000 | 649,624 | |||||||||||||||||||||
2020 | 197,691 | — | 696,142 | 66,490 | 6,589 | 966,91 | ||||||||||||||||||||||
Howard Levy (5) Former Chief Medical Officer |
2021 | 326,895 | — | 252,037 | — | 39,322 | 618,254 | |||||||||||||||||||||
2020 | 450,348 | — | 249,670 | 112,342 | 14,349 | 826,709 |
(1) |
The amounts in this column reflect the aggregate grant date fair value of restricted stock awarded during the year calculated in accordance with Financial Accounting Standards Board Accounting Standards Codification Compensation-Stock Compensation (Topic 718), or ASC 718, disregarding the potential for forfeitures, regardless of the period in which the corresponding compensation expense was recorded in accordance with ASC 718. |
(2) |
These amounts reflect bonuses earned based upon our achievement of certain product development and business objectives. |
(3) |
The amounts in this column for Drs. Usman and Levy and Mr. Musil for 2020 represent payment of life insurance premiums. The amount in this column for Dr. Usman for 2021 represents payment of long-term disability. The amounts in this column for 2021 for Dr. Levy and Mr. Musil represent payment of consulting fees. |
(4) |
Effective August 15, 2021, Mr. Musil ceased to be an executive officer. |
(5) |
Effective October 29, 2021, Dr. Levy ceased to be an executive officer. |
• | continued base salary for twelve (12) months after the termination (the “ Usman Severance Period ”); |
• | accelerated vesting of options that would otherwise have vested during the Usman Severance Period; and |
• | payment by the Company of the same portion of his monthly premium under COBRA as it pays for active employees until the close of the Usman Severance Period. |
• | severance payments, equal to the sum of (a) 150% of his annual base salary and (b) 150% of his maximum annual performance-based bonus, paid in equal installments for eighteen (18) months after the termination (the “ Usman ”); Post-COC Severance Period |
• | accelerated vesting of 100% percent of any unvested options; and |
• | payment by the Company of the same portion of his monthly premium under COBRA as it pays for active employees until the close of the Usman Post-COC Severance Period. |
• | continued base salary for nine (9) months after the termination (the “ Blouse Severance Period ”); |
• | accelerated vesting of options that would otherwise have vested during the Blouse Severance Period; and |
• | payment by the Company of the same portion of his monthly premium under COBRA as it pays for active employees until the close of the Blouse Severance Period. |
• | severance payments, equal to the sum of (a) 100% of his annual base salary and (b) 100% of his maximum annual performance-based bonus, paid in equal installments for twelve (12) months after the termination (the “ Blouse ”); Post-COC Severance Period |
• | accelerated vesting of 100% percent of any unvested options; and |
• | payment by the Company of the same portion of his monthly premium under COBRA as it pays for active employees until the close of the Blouse Post-COC Severance Period. |
• | continued base salary for nine (9) months after the termination (the “ Miller Severance Period ”); |
• | accelerated vesting of options that would otherwise have vested during the Miller Severance Period; and |
• | payment by the Company of the same portion of his monthly premium under COBRA as it pays for active employees until the close of the Miller Severance Period. |
• | severance payments, equal to the sum of (a) 100% of her annual base salary and (b) 100% of her maximum annual performance-based bonus, paid in equal installments for twelve (12) months after the termination (the “ Miller ”); Post-COC Severance Period |
• | accelerated vesting of 100% percent of any unvested options; and |
• | payment by the Company of the same portion of her monthly premium under COBRA as it pays for active employees until the close of the Miller Post-COC Severance Period. |
Name |
Grant Date |
FN |
Number of Securities Underlying Unexercised Option Exercisable(#) |
Number of Securities Underlying Unexercised Option Unexercisable(#) |
FN |
Option Exercise Price($) |
Option Expiration Date |
|||||||||||||||||||||
Nassim Usman, Ph. D. |
8/20/2015 | (1 ) |
1,500 | — | (2) |
172.80 | 1/3/2023 | |||||||||||||||||||||
10/22/2015 | (1) |
14,999 | — | (3) |
66.00 | 10/22/2025 | ||||||||||||||||||||||
7/11/2017 | 259,783 | — | (4) |
4.63 | 7/11/2027 | |||||||||||||||||||||||
1/12/2018 | 83,125 | 11,875 | (5) |
15.13 | 1/12/2028 | |||||||||||||||||||||||
7/30/2018 | 65,625 | 9,375 | (6) |
9.68 | 7/30/2028 | |||||||||||||||||||||||
1/24/2019 | 58,333 | 21,667 | (7) |
7.97 | 1/24/2029 | |||||||||||||||||||||||
1/23/2020 | 55,104 | 59,896 | (8) |
6.85 | 1/23/2030 | |||||||||||||||||||||||
2/8/2021 | — | 140,000 | (9) |
5.89 | 2/8/2031 | |||||||||||||||||||||||
Grant Blouse, Ph.D. |
7/16/2018 | 25,625 | 4,375 | (10) |
12.21 | 7/16/2028 | ||||||||||||||||||||||
7/30/2018 | 8,542 | 1,458 | (11) |
9.68 | 7/30/2028 | |||||||||||||||||||||||
1/24/2019 | 13,125 | 4,875 | (12) |
7.97 | 1/24/2029 | |||||||||||||||||||||||
1/23/2020 | 16,771 | 18,229 | (13) |
6.85 | 1/23/2029 | |||||||||||||||||||||||
2/8/2021 | — | 38,500 | (9) |
5.89 | 2/8/2031 | |||||||||||||||||||||||
6/16/2021 | — | 25,000 | (14) |
4.33 | 6/16/2031 | |||||||||||||||||||||||
Seline Miller |
4/15/2021 | — | 16,000 | (15) |
4.81 | 4/15/2031 | ||||||||||||||||||||||
Clinton Musil |
7/1/2020 | 43,750 | — | (16) |
5.88 | 7/1/2030 | ||||||||||||||||||||||
Howard Levy (17) |
4/8/2016 | 6,666 | — | 22.80 | 4/18/2026 | |||||||||||||||||||||||
7/11/2017 | 81,218 | — | 4.63 | 7/11/2027 | ||||||||||||||||||||||||
1/12/2018 | 29,563 | — | 15.13 | 1/12/2028 | ||||||||||||||||||||||||
7/30/2018 | 27,708 | — | 9.68 | 7/30/2028 | ||||||||||||||||||||||||
1/24/2019 | 21,875 | — | 7.97 | 1/24/2029 | ||||||||||||||||||||||||
1/23/2020 | 16,875 | — | 6.85 | 1/23/2030 |
(1) |
These stock options were granted by the Board on the grant dates listed but were assumed by the Company upon the closing of the merger on August 20, 2015 and converted into options to purchase common stock of the Company as described in the table. |
(2) |
These options became fully vested on August 20, 2019. |
(3) |
These options became fully vested on September 1, 2019. |
(4) |
These options became fully vested on June 15, 2021. |
(5) |
The remaining portion of these options to purchase common stock vests at the rate of 1/48th of the total number of shares subject to the option on the 12th day of each month, with the final tranche vesting on January 12, 2022. |
(6) |
The remaining portion of these options to purchase common stock vests at the rate of 1/48th of the total number of shares subject to the option on the 13th day of each month, with the final tranche vesting on June 13, 2022. |
(7) |
The remaining portion of these options to purchase common stock vests at the rate of 1/48th of the total number of shares subject to the option on the 24th day of each month, with the final tranche vesting on January 24, 2022. |
(8) |
The remaining portion of these options to purchase common stock vests at the rate of 1/48th of the total number of shares subject to the option on the 23rd day of each month, with the final tranche vesting on January 23, 2024. |
(9) |
These options to purchase common stock vest at the rate of 1/4 of the total number of shares subject to the option on February 8, 2022 and at the rate of 1/48th of the total number of shares subject to the option on the 23rd day of each month thereafter, with the final tranche vesting on February 8, 2025. |
(10) |
The remaining portion of these options to purchase common stock vests at the rate of 1/48th of the total number of shares subject to the option on the 2nd day of each month, with the final tranche vesting on July 2, 2022. |
(11) |
The remaining portion of these options to purchase common stock vests at the rate of 1/48th of the total number of shares subject to the option on the 1st day of each month, with the final tranche vesting on July 1, 2022. |
(12) |
The remaining portion of these options to purchase common stock vests at the rate of 1/48th of the total number of shares subject to the option on the 24th day of each month, with the final tranche vesting on January 24, 2023. |
(13) |
The remaining portion of these options to purchase common stock vests at the rate of 1/48th of the total number of shares subject to the option on the 23rd day of each month, with the final tranche vesting on January 23, 2024. |
(14) |
These options to purchase common stock vest at the rate of 1/4 of the total number of shares subject to the option on June 16, 2022 and at the rate of 1/48th of the total number of shares subject to the option on the 16th day of each month thereafter, with the final tranche vesting on June 16, 2025. |
(15) |
These options to purchase common stock vest at the rate of 1/4 of the total number of shares subject to the option on March 29, 2022 and at the rate of 1/48th of the total number of shares subject to the option on the 29th day of each month thereafter, with the final tranche vesting on March 29, 2025. |
(16) |
These options were fully vested as of October 29, 2021, the date of Mr. Musil’s resignation from the Company |
(17) |
The options listed for Dr. Levy were fully vested as of August 15, 2021, the date of Dr. Levy’s retirement from the Company. |
• | Initial Equity Grants. Each non-employee director who joins the Board will receive an option to purchase 28,000 shares of common stock, which will vest over three years, subject to continued service. |
• | Annual Retainers. Each non-employee director will receive an annual retainer for service on the Board consisting of an option to purchase 14,000 shares of the common stock, to be awarded at the Company’s annual stockholders’ meeting and which will vest over one year. This is in addition to annual cash retainers for service on the Board and committees of the Board, or for service as chair of the Board or such committees (inclusive of retainers for service as a member), which are paid quarterly and which amounts are as follows: |
Additional annual retainer fees for service as member or chair of |
Member |
Chair |
||||||
Board of Directors |
$ | 40,000 | $ | 75,000 | ||||
Audit Committee |
$ | 9,000 | $ | 18,000 | ||||
Compensation Committee |
$ | 7,000 | $ | 14,000 | ||||
Governance and Nominating Committee |
$ | 5,000 | $ | 10,000 |
Name |
Fees Earned or Paid in Cash ($) |
Option Awards ($) (1)(2) |
Stock Grants ($) (3) |
Total ($) |
||||||||||||
Augustine Lawlor |
22,750 | 46,478 | 71,991 | 141,219 | ||||||||||||
Andrea Hunt |
10,625 | 46,478 | 39,336 | 96,439 | ||||||||||||
Eddie Williams |
12,250 | 46,478 | 35,694 | 94,422 | ||||||||||||
Errol B. De Souza |
14,750 | 46,478 | 44,242 | 105,470 | ||||||||||||
Geoffrey Ling |
— | 46,478 | 46,940 | 93,418 | ||||||||||||
Jeanne Jew |
12,250 | 90,213 | — | 102,463 | ||||||||||||
Sharon Tetlow |
58,000 | 46,478 | — | 104,478 |
(1) |
The amounts in this column reflect the aggregate grant date fair value of stock options granted during the fiscal year ended December 31, 2021 calculated in accordance with ASC 718, disregarding the potential for forfeitures. |
(2) |
The following table sets forth the aggregate number of option awards held by each non-employee director serving in 2021 as of December 31, 2021: |
Name |
Aggregate Number of Option Awards |
|||
Augustine Lawlor |
40,500 | |||
Andrea Hunt |
39,000 | |||
Eddie Williams |
41,581 | |||
Errol B. De Souza |
29,000 | |||
Geoffrey Ling |
29,000 | |||
Jeanne Y. Jew |
28,000 | |||
Sharon Tetlow |
29,000 |
(3) |
The amounts in this column reflect the board of director fees board members elected to receive in fully vested non-restricted common stock awards in lieu of cash compensation. |
Plan Category |
Number of Securities to be Issued Upon Exercise of Outstanding Options Warrants and Rights (A) |
Weighted-Average Exercise Price of Outstanding Options (B) |
Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (A)) (C) |
|||||||||
Equity compensation plans approved by security holders (1) |
2,599,201 | $ | 7.62 | 3,566,260 | (2) | |||||||
Equity compensation plans not approved by security holders (3) |
7,429 | $ | 32.17 | – | ||||||||
Total |
2,606,630 | $ | 39.79 | 3,566,260 |
(1) |
Includes shares issued or issuable upon the exercise of stock option or other stock-based awards under the 2018 Plan, the 2015 Plan and the 2006 Plan. |
(2) |
Includes 3,330,791 shares available for issuance under the 2018 Plan and 235,469 shares available for issuance under the ESPP, including shares subject to purchase during the current purchase period, which commenced on February 10, 2022 (the exact number of which will not be known until the purchase date on August 9, 2022). In addition, the ESPP provides for an annual increase to the number of shares of our common stock available for issuance thereunder on the first business day of each calendar year, equal to the lesser of (x) 120,000 shares, (y) 1.0 percent of the number of shares of our common stock outstanding as of the last day of the immediately preceding calendar year, and (z) a lesser number of shares determined by the ESPP administrator. |
(3) |
Includes an aggregate of 763 shares issuable upon the exercise of standalone options with a weighted average exercise price of $114.00, issued to Dr. Hansoo Keyoung by Catalyst and assumed in connection with the merger (the “ Keyoung Grants ”). Also includes 6,666 shares issuable upon the exercise of a standalone option with an exercise price of $22.80, issued to Dr. Levy, as a material inducement to the decision of Dr. Levy to accept employment as Chief Medical Officer of the Company (the “Levy Grant ”). |
(1) | each person or group of affiliated persons known by us to be the beneficial owner of more than 5% of our common stock; |
(2) | each of our named executive officers; |
(3) | each of our directors; and |
(4) | all current executive officers and directors as a group. |
Name |
Number of Shares Owned and Nature of Beneficial Ownership |
Percent of Class |
||||||
5% or Greater Stockholders |
||||||||
Nantahala Capital Management, LLC |
2,761,660 | (1) |
8.8 | % | ||||
Laurence W. Lytton |
1,864,115 | (2) |
5.9 | % | ||||
Renaissance Technologies LLC |
1,771,908 | (3) |
5.6 | % | ||||
OrbiMed Capital LLC |
1,729,402 | (4) |
5.5 | % | ||||
JDS1, LLC |
1,651,132 | (5) |
5.2 | % | ||||
Directors and Named Executive Officers |
||||||||
Nassim Usman, Ph.D. |
651,156 | (6) |
2.0 | % | ||||
Grant Blouse |
91,948 | (7) |
* |
|||||
Seline Miller |
7,917 | (8) |
* |
|||||
Augustine Lawlor |
75,288 | (9) |
* |
|||||
Andrea Hunt |
53,228 | (10) |
* |
|||||
Eddie Williams |
59,804 | (10) |
* |
|||||
Errol B. De Souza |
57,382 | (11) |
* |
|||||
Geoffrey Ling |
44,568 | (12) |
* |
|||||
Jeanne Y. Jew |
— | — | ||||||
Sharon Tetlow |
16,413 | (12) |
* |
|||||
All Directors and Executive Officers as a Group (10 persons) |
1,057,704 | 3.3 | % |
* |
Indicates less than 1% of class. |
(1) |
The information reported is based on a Schedule 13G/A filed with the SEC on February 14, 2022. The shares are held directly by Nantahala Capital Management, LLC (“ Nantahala ”). Wilmot B. Harkey and Daniel Mack, as managing members of Nantahala, may be deemed to have shared voting and dispositive power of these shares. The principal business address of Nantahala is 130 Main St. 2nd Floor, New Canaan, CT 06840. |
(2) |
The information reported is based on a Schedule 13G filed with the SEC on March 4, 2022. The shares are held directly by Laurence W. Lytton. The principal business address of Mr. Lytton is 467 Central Park West, New York, NY 10025. |
(3) |
The information reported is based on a Schedule 13G filed jointly by Renaissance Technologies LLC (“ Renaissance ”) and Renaissance Technologies Holdings Corporation (“Renaissance Holdings ”) with the SEC on February 11, 2022. The shares are held directly by Renaissance. Renaissance Holdings is the majority owner of Renaissance and as such, may be deemed to beneficially own the shares held by Renaissance. Renaissance and Renaissance Holdings have sole voting power over 1,347,877 shares held by Renaissance and shared dispositive power over 1,771,908 shares held by Renaissance. The principal business address of Renaissance and Renaissance Holdings is 800 Third Avenue, New York, New York 10022. |
(4) |
The information reported is based on a Schedule 13G filed jointly by OrbiMed Capital LLC (“ OrbiMed Capital ”) and OrbiMed Advisors LLC (“OrbiMed Advisors”) with the SEC on February 11, 2022. OrbiMed Capital directly holds, and has sole voting and dispositive power over, 1,350,602 shares. OrbiMed Advisors directly holds, and has shared voting and dispositive power over, 378,800 shares. OrbiMed Capital and OrbiMed Advisors directly hold such shares on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale, of such shares. OrbiMed Capital and OrbiMed Advisors exercise investment and voting power over the shares through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of such shares. The principal business address of OrbiMed Capital and OrbiMed Advisors is 601 Lexington Avenue, 54th Floor, New York, NY 10022. |
(5) |
The information reported is based on a Schedule 13D/A filed jointly by JDS 1, LLC (“JDS1”), CCUR Holdings, Inc (“CCUR Holdings”), CIDM II, LLC (“CIDM II”), Julian D. Singer, David S. Oros, Shelly C. Lombard, Matthew Stecker and Igor Volshteyn with the SEC on March 16, 2022. JDS1 may be deemed the beneficial owner of 1,312,532 shares comprised of (i) the 780,432 shares beneficially owned and held directly by JDS1, and (ii) as an affiliate of CCUR, the 532,100 shares beneficially owned and held directly by CCUR. CCUR beneficially owned 532,100 shares, which shares are held directly by CCUR. CIDM II, as the asset manager to CCUR, may be deemed the beneficial owner of the 532,100 Shares beneficially owned by CCUR. Mr. Singer, as the managing member of JDS1 and CIDM II, may be deemed the beneficial owner of 1,312,532 shares of Common Stock. Mr. Singer does not own any shares directly. Mr. Oros beneficially owned 338,600 Shares, which shares are held directly by him. None of Ms. Lombard and Messrs. Stecker and Volshteyn beneficially owned any shares. The principal business address of each of JDS1, CIDM II, and Mr. Singer is 2200 Fletcher Avenue, Suite 501, Fort Lee, New Jersey 07024. The address of the principal office of CCUR is 3800 N Lamar Boulevard, Suite 200, Austin, Texas 78756. The address of the principal office of Mr. Oros is 702 W. Lake Avenue, Baltimore, Maryland 21210. The address of the principal office of Ms. Lombard is 44 Morse Avenue, Bloomfield, NJ 07003. The address of the principal office of Mr. Stecker is c/o Evolving Systems, Inc., 9800 Pyramid Court, Suite 400, Englewood, CO 80112. The address of the principal office of Mr. Volshteyn is c/o CCUR Holdings, Inc., 3800 N Lamar Boulevard, Suite 200, Austin, Texas 78756. |
(6) |
Includes (i) 8,456 shares held by the Usman Family Trust, of which Dr. Usman is a co-trustee with Susan L. Usman, (ii) 1,168 shares held in an IRA, and (iii) 620,241 shares issuable upon the exercise of options that are vested and exercisable within 60 days of March 31, 2022. |
(7) |
Includes 85,781 shares issuable upon the exercise of options that are vested and exercisable within 60 days of March 31, 2022. |
(8) |
Includes 4,667 shares issuable upon the exercise of options that are vested and exercisable within 60 days of March 31, 2022. |
(9) |
Includes (i) 24,215 shares held by the Lawlor Family Trust UAD 4-17-00, |
(10) |
Includes 25,000 shares issuable upon the exercise of options that are vested and exercisable within 60 days of March 31, 2022. |
(11) |
Includes 27,581 shares issuable upon the exercise of options that are vested and exercisable within 60 days of March 31, 2022. |
(12) |
Includes 12,778 shares issuable upon the exercise of options that are vested and exercisable within 60 days of March 31, 2022. |
• | transactions in which the amount involved exceeds the lesser of $120,000 or one percent of the average of the smaller reporting company’s total assets at year-end for the last two completed fiscal years; and |
• | any of the directors, executive officers, holders of more than 5% of capital stock (sometimes referred to as “5% stockholders” below) of the Company or any member of their immediate family had or will have a direct or indirect material interest (other than transactions described under the heading “Executive Compensation”). |
Fiscal 2021 |
Fiscal 2020 |
|||||||
Audit Fees (1) |
$ | 228,800 | $ | 303,903 | ||||
Audit-Related Fees: |
— | — | ||||||
Tax Fees: |
— | — | ||||||
All Other Fees (2) : |
$ | 97,775 | — | |||||
Total Fees: |
$ | 326,575 | $ | 303,903 |
(1) |
Audit Fees include fees billed for the applicable year for services in connection with the audit of the Company’s financial statements included in its Annual Report on Form 10-K, quarterly reports on Form 10-Q and registration statements on Forms S-3 and S-8. |
(2) |
All Other Fees includes fees billed for the applicable year for comfort letters and consent letters delivered. |
Exhibit Number |
Incorporated by Reference |
Filed Herewith | ||||||||||
Exhibit Description |
Form |
File No. |
Exhibit |
Filing Date | ||||||||
31.03 | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||||||||
31.04 | Certification of Interim Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||||||||
104 | Cover Page Interactive Data File (formatted as Inline XBRL) | X |
CATALYST BIOSCIENCES, INC . | ||||||
(Registrant) | ||||||
Date: May 2, 2022 | /s/ Nassim Usman, Ph.D. | |||||
Nassim Usman, Ph.D. | ||||||
President and Chief Executive Officer | ||||||
(Principal Executive Officer) | ||||||
Date: May 2, 2022 | /s/ Seline Miller | |||||
Seline Miller | ||||||
Interim Chief Financial Officer | ||||||
(Principal Financial and Accounting Officer) |
Exhibit 31.03
CERTIFICATION PURSUANT TO RULE 13a-14(a) AND 15d-14(a) OF THE SECURITIES EXCHANGE ACT
OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Nassim Usman, certify that:
1. I have reviewed this Amendment No.1 to the Annual Report on Form 10-K/A of Catalyst Biosciences, Inc; and
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
Date: May 2, 2022 | /s/ Nassim Usman, Ph.D. | |||||
Nassim Usman, Ph.D. Interim Chief Executive Officer (Principal Executive Officer) |
Exhibit 31.04
CERTIFICATION PURSUANT TO RULE 13a-14(a) AND 15d-14(a) OF THE SECURITIES EXCHANGE ACT
OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Seline Miller, certify that:
1. I have reviewed this Amendment No.1 to the Annual Report on Form 10-K/A of Catalyst Biosciences, Inc; and
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
Date: May 2, 2022 | /s/ Seline Miller | |||||
Seline Miller Interim Chief Financial Officer (Interim Principal Financial and Accounting Officer) |